01—Abstract
Summary
Summary of the 10-Q filed August 3, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. reported a significant decline in revenue for the three and six months ended June 30, 2023, primarily driven by a steep drop in COVID-19 vaccine product sales.
Total revenue fell by 93% and 80% year-over-year for the respective periods. This revenue contraction led to a substantial net loss of $1.38 billiona for the quarter and $1.30 billion for the six months, a stark contrast to the profits reported in the prior year. The company is actively managing its transition from a pandemic-driven market to a more endemic and seasonal one for its COVID-19 vaccine, which is impacting sales and leading to increased inventory write-downs and unutilized manufacturing capacity costs.
Despite the revenue challenges, Moderna is making strategic investments in its pipeline. Research and development expenses increased by 62%b and 80% for the respective periods, reflecting progress in key programs like RSV, influenza, and CMV vaccines, as well as advancements in its individualized neoantigen therapy.
The company also reported significant cash reserves and a strong balance sheet, with $3.8 billionc in cash and cash equivalents and substantial investments, providing a buffer for continued R&D and operational needs. The company expects its cash position to be sufficient for at least the next 12 months, though it acknowledges the potential for future operating cash flow fluctuations.
02—Key points
Key Highlights
- Significant revenue decline in Q2 2023: Product sales decreased by 94% year-over-year to $293 million, leading to a net loss of $1.38 billion.
- Shift to endemic COVID-19 vaccine market impacts sales and costs: Higher inventory write-downs and unutilized manufacturing capacity expenses ($464 million and $135 million respectively in Q2 2023) are noted due to declining demand and a shift to variant-specific vaccines.
- Robust R&D investment continues: Research and development expenses increased by 62% in Q2 2023 to $1.15 billion, supporting pipeline advancement in RSV, flu, CMV, and oncology.
- Positive clinical trial progress for key pipeline assets: Initiated pivotal Phase 3 for individualized neoantigen therapy (mRNA-4157) with Merck and advanced regulatory submissions for RSV vaccine (mRNA-1345).
- Strong cash position maintained: Cash and cash equivalents stood at $3.8 billion as of June 30, 2023, with total investments of $10.8 billion, ensuring liquidity.
- Share repurchases continue: The company repurchased $1.15 billion of common stock in the first half of 2023, underscoring a commitment to returning capital to shareholders.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2023filed August 3, 2023Financial Statements
Q2 FY2023 against Q2 FY2022
| Line item | Q2 FY2023Q2 FY2022 | Change |
|---|---|---|
| Revenue | $344.00M$4.75B | −92.8% |
| Cost of Revenue | $731.00M$1.38B | −47.1% |
| Gross Profit | -$387.00M$3.37B | −111.5% |
| R&D Expenses | $1.15B$710.00M | +61.7% |
| Operating Expenses | $2.21B$2.30B | −4.0% |
| Operating Income | -$1.87B$2.45B | −176.3% |
| Net Income | -$1.38B$2.20B | −162.8% |
| EPS (Basic) | $-3.62$5.55 | −165.2% |
| EPS (Diluted) | $-3.62$5.24 | −169.1% |
| Shares Outstanding (Basic) | 381.00M396.00M | −3.8% |
| Shares Outstanding (Diluted) | 381.00M419.00M | −9.1% |
05—Questions
Frequently Asked Questions
What is the primary driver of Moderna's substantial revenue decrease in the reported quarter?
The primary driver is the significant decline in COVID-19 vaccine product sales. Revenue from product sales dropped by 94% year-over-year to $293 million in the second quarter of 2023, reflecting the market's shift from a pandemic to an endemic and seasonal one.
How is Moderna addressing the increased costs associated with the declining COVID-19 vaccine market?
Moderna is experiencing increased costs such as inventory write-downs and unutilized manufacturing capacity, which were $464 million and $135 million respectively in Q2 2023. These are driven by reduced demand and the shift to newer variant-specific vaccines, rendering older inventory obsolete. The company expects these cost pressures to continue as it navigates the transition to an endemic market.
What are the key areas of investment for Moderna's increased Research and Development (R&D) spending?
Moderna's R&D expenses increased significantly to support its pipeline. Key areas include clinical development for its RSV, influenza (flu), and Cytomegalovirus (CMV) vaccine candidates, as well as its individualized neoantigen therapy (mRNA-4157) in collaboration with Merck. Progress on new candidates for Lyme disease and norovirus is also contributing.
What is Moderna's current financial health and liquidity situation?
Moderna maintains a strong liquidity position with $3.8 billion in cash and cash equivalents and $10.8 billion in total marketable securities as of June 30, 2023. Despite a net loss in the quarter and the cash used in operations, the company believes its current financial resources are sufficient to fund operations and capital expenditures for at least the next 12 months.
06—Continue